CardioExchange Archive

October 20th, 2010

Finally: Dabigatran – A New Oral Anticoagulant Is Approved by the FDA

Westby G Fisher, MD

CardioExchange welcomes this guest post reprinted with permission from Dr. Westby Fisher, an electrophysiologist practicing at NorthShore University HealthSystem, Evanston, IL, and a Clinical Associate Professor of Medicine at University of Chicago’s Pritzker School of Medicine. This piece originally appeared on his blog, Dr. Wes. A new era of nonvalvular atrial fibrillation management has arrived. Tuesday, the FDA approved the first new […]

---

October 20th, 2010

Dabigatran Is Approved

John Mandrola, MD, FACC

John Mandrola is a cardiac electrophysiologist and blogger on matters medical and general. Here is a recent post from his blog Dr John M. There can only be one cardiology story to discuss today. Tuesday, the FDA approved dabigatran (Pradaxa), an oral anticoagulant for the prevention of stroke in atrial fibrillation. Previously, the only drug approved to prevent stroke in […]

---

September 21st, 2010

See Everything

John Mandrola, MD, FACC

John Mandrola is a cardiac electrophysiologist and blogger on matters medical and general. Here is a recent post from his blog Dr John M. Do you see anything wrong with this picture? (Hint: see the right column) I guess the European electrophysiologists couldn’t wait for us in North America.  They have published their own 54,000 word Euro-specific guidance […]

---

August 31st, 2010

The CURE for Clopidogrel Genotyping?

Guillaume Pare, MD, MSc

CardioExchange welcomes Guillaume Paré to discuss his team’s work on the  utility of clopidogrel genotyping. The researchers genotyped for CYP2C19 alleles associated with loss-of-function or gain-of-function of clopidogrel in some 5,000 patients with ACS or A-fib from two large randomized trials. In both studies, clopidogrel had similar efficacy over placebo regardless of whether patients had […]

---

August 29th, 2010

Superiority of Dabigatran More Evident in Places Where INR Is Not Well Controlled

Larry Husten, PHD

At last year’s ESC meeting, the RE-LY trial heightened interest in the prospect of dabigatran as a potential replacement for warfarin. Now the RE-LY investigators have analyzed the trial data in an attempt to see whether the local standard of care has an impact on the beneficial effects of switching to dabigatran. In a presentation […]

---